Prescribing Information
PATIENT SITE

DARZALEX FASPRO® DOSING & ADMINISTRATION GUIDE

DARZALEX® DOSING & ADMINISTRATION GUIDE

INDICATIONS AND DOSING

Newly Diagnosed
- DVRd
- DRd
- DVMP
- DVTd
Relapsed or Refractory

NCCN RECOMMENDATIONS

PATIENT PROFILE

PROVEN EFFICACY

DEMONSTRATED SAFETY

PROVEN EFFICACY

DEMONSTRATED SAFETY

HIGH-RISK SUBGROUP

FRAILTY SUBGROUP

CONTINUING DRd TREATMENT

MAINTAINING TREATMENT BENEFITS

TIME TO DEEPEST RESPONSE

SAFETY OVER TIME

ADVANCING PATIENT CARE

PRACTICE SUPPORT

PATIENT SUPPORT

MECHANISM OF ACTION

FOR APPs & NURSES

PRESCRIBING INFORMATION
Important Safety Information
- DARZALEX FASPRO^® Important Safety Information
- DARZALEX^® Important Safety Information
Contact Us
Dosing & Administration Guide
- DARZALEX FASPRO^® Dosing & Administration Guide
- DARZALEX^® Dosing & Administration Guide
PATIENT SITE
MM Portfolio
This site is intended for
US healthcare professionals.

Choose DARZALEX FASPRO^® to treat newly diagnosed patients with multiple myeloma, regardless of transplant status

Site Map

Home
Site Map

Product Use
Frontline DVRd
Frontline DRd
Continuing DRd treatment
Resources
For APPs and Nurses

Medical Information Center
Site Map